Pathologists at the Stanford University School of Medicine are trying out a new test from a Sunnyvale company that could give cancer patients a better chance of getting the most effective treatment.

UK-based AI and machine learning firm PinPoint has raised more than £1 million to develop a test designed to rule out cancer in the early stages and save millions for the NHS in unnecessary testing.

Life Technologies acquired Pinpoint Genomics and its early-stage non-small-cell lung cancer test. The test is designed to identify early-stage patients at high risk for progression to late-stage ...

CARLSBAD, Calif., July 25, 2012 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) today announced the acquisition of Pinpoint Genomics, Inc., and its early-stage non-small cell lung cancer ...

Colon cancer is one of the top three deadliest forms of cancer - in part because it's often diagnosed so late. Now a groundbreaking study could pinpoint the disease easier, and earlier. The ...

A pioneering AI-enabled multi-cancer blood test, developed with the NHS in England, will be among the headline innovations featured on the UK Pavilion at WHX Dubai 2026, as UK HealthTech takes the ...